/ADIL
ADIL Stock - Adial Pharmaceuticals, Inc.
Healthcare|BiotechnologyNASDAQ
$0.24-8.14%
$0.02 (-8.14%) • Dec 19
50
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.76
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.26
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ADIL
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.24 – $0.24
TARGET (TP)$0.28
STOP LOSS$0.22
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.11
52W High$1.30
52W Low$0.22
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | $-564 | N/A | N/A | $-564 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-8,284,457 | $-6,887,947 | $-10,859,475 | $-19,288,723 | $-10,927,985 |
| Net Income | $-13,197,451 | $-7,001,890 | $-12,731,416 | $-19,423,326 | $-10,860,495 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-0.71 | $-5.44 | $-11.98 | $-26.12 | $-21.79 |
Company Overview
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
1
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
1 Bullish0 Neutral/Bearish
Price Targets
$8
Average Target
↑ 3226.4% Upside
Now
$8
Low
$8
Average
$8
High
Based on 1 analyst
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 14th 2024 | Rodman & Renshaw | Initiation | Buy | $8 |
Earnings History & Surprises
ADILBeat Rate
56%
Last 18 quarters
Avg Surprise
-342.1%
EPS vs Estimate
Beats / Misses
10/5
3 met exactly
Latest EPS
$-0.08
Q4 2025
EPS Surprise History
Q2 24
-77.6%
$-1.35vs$-0.76
Q2 24
-33.3%
$-0.68vs$-0.51
Q3 24
-51.3%
$-0.59vs$-0.39
Q4 24
+24.0%
$-0.38vs$-0.50
Q1 25
+60.5%
$-0.15vs$-0.38
Q2 25
+32.0%
$-0.34vs$-0.50
Q3 25
+18.2%
$-0.18vs$-0.22
Q4 25
+11.1%
$-0.08vs$-0.09
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 12, 2026 | — | — | — | — |
Q1 2026 | Mar 3, 2026 | $-0.08 | — | — | — |
Q4 2025 | Nov 13, 2025 | $-0.09 | $-0.08 | +11.1% | ✓ BEAT |
Q3 2025 | Aug 13, 2025 | $-0.22 | $-0.18 | +18.2% | ✓ BEAT |
Q2 2025 | May 14, 2025 | $-0.50 | $-0.34 | +32.0% | ✓ BEAT |
Q1 2025 | Mar 4, 2025 | $-0.38 | $-0.15 | +60.5% | ✓ BEAT |
Q4 2024 | Nov 13, 2024 | $-0.50 | $-0.38 | +24.0% | ✓ BEAT |
Q3 2024 | Aug 13, 2024 | $-0.39 | $-0.59 | -51.3% | ✗ MISS |
Q2 2024 | May 14, 2024 | $-0.51 | $-0.68 | -33.3% | ✗ MISS |
Q2 2024 | Apr 1, 2024 | $-0.76 | $-1.35 | -77.6% | ✗ MISS |
Q4 2023 | Nov 14, 2023 | $-1.14 | $-1.14 | 0.0% | = MET |
Q3 2023 | Aug 21, 2023 | $-1.50 | $-1.33 | +11.3% | ✓ BEAT |
Q2 2023 | May 12, 2023 | $-3.50 | $-2.75 | +21.4% | ✓ BEAT |
Q1 2023 | Mar 30, 2023 | $-3.75 | $-2.75 | +26.7% | ✓ BEAT |
Q4 2022 | Nov 14, 2022 | $-4.50 | $-3.00 | +33.3% | ✓ BEAT |
Q3 2022 | Aug 16, 2022 | $-4.00 | $-4.00 | 0.0% | = MET |
Q2 2022 | May 16, 2022 | $-4.25 | $-3.25 | +23.5% | ✓ BEAT |
Q1 2022 | Mar 28, 2022 | $-0.21 | $-7.00 | -3233.3% | ✗ MISS |
Q4 2021 | Nov 15, 2021 | $-5.50 | $-5.50 | 0.0% | = MET |
Q3 2021 | Aug 12, 2021 | $-0.20 | $-6.25 | -3025.0% | ✗ MISS |
Latest News
Adial Pharmaceuticals Secures $2.86M As Investor Exercises 9.2M Warrants At $0.31; Company To Issue 13.8M New Series F Warrants At Same Price
📈 PositiveBenzinga•Nov 26, 2025, 01:04 PM
Adial Pharmaceuticals Q3 Net Loss $1.8M
📉 NegativeBenzinga•Nov 14, 2025, 01:39 PM
Adial Pharma Completes Analytical Validation Of Cheek Swab Collection Method For Testing Patients For Both Clinical Trial Usage As Well As Future Commercial Application
📈 PositiveBenzinga•Oct 9, 2025, 12:40 PM
Maxim Group Upgrades Adial Pharmaceuticals to Buy, Announces $1.5 Price Target
📈 PositiveBenzinga•Sep 30, 2025, 12:32 PM
EXCLUSIVE: Adial Pharmaceuticals Tells Benzinga 'FDA Minutes Reflect Constructive Dialogue and Successful Meeting Outcome with Alignment on Upcoming Phase 3 Clinical Trial Design for AD04 In Alcohol Use Disorder'
📈 PositiveBenzinga•Sep 16, 2025, 12:00 PM
EXCLUSIVE: Adial Pharmaceuticals Tells Benzinga Co. Provides Business Update Following Favorable Comments From FDA End-Of- Phase 2 (EOP2) Meeting For AD04
📈 PositiveBenzinga•Sep 16, 2025, 12:00 PM
Adial Pharma Receives 180-Day Nasdaq Extension To Regain Minimum Bid Price Compliance
➖ NeutralBenzinga•Sep 3, 2025, 12:42 PM
Adial Pharma Highlights U.S. Senate Backing For Expanded AUD Trial Endpoints, Reinforcing AD04 Development Strategy Focused On Craving Reduction
📈 PositiveBenzinga•Aug 20, 2025, 12:41 PM
Frequently Asked Questions about ADIL
What is ADIL's current stock price?
Adial Pharmaceuticals, Inc. (ADIL) is currently trading at $0.24 per share. The stock has moved -8.14% today.
What is the analyst price target for ADIL?
No analyst price targets are currently available for this stock.
What sector is Adial Pharmaceuticals, Inc. in?
Adial Pharmaceuticals, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is ADIL's market cap?
Adial Pharmaceuticals, Inc. has a market capitalization of $0.01 billion, making it a small-cap company.
Does ADIL pay dividends?
No, Adial Pharmaceuticals, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACXP
Acurx Pharmaceuticals, Inc.
$3.33
Mkt Cap: $0.0B
APRE
Aprea Therapeutics, Inc.
$0.93
Mkt Cap: $0.0B
BCDA
BioCardia, Inc.
$1.27
Mkt Cap: $0.0B
BCLI
Brainstorm Cell Therapeutics Inc.
$0.56
Mkt Cap: $0.0B
CDIO
Cardio Diagnostics Holdings, Inc.
$3.23
Mkt Cap: $0.0B
CELZ
Creative Medical Technology Holdings, Inc.
$2.11
Mkt Cap: $0.0B
HCWB
HCW Biologics Inc.
$1.57
Mkt Cap: $0.0B
KPRX
Kiora Pharmaceuticals, Inc.
$2.16
Mkt Cap: $0.0B
MTNB
Matinas BioPharma Holdings, Inc.
$0.73
Mkt Cap: $0.0B
NRSN
NeuroSense Therapeutics Ltd.
$0.81
Mkt Cap: $0.0B
Explore stocks similar to ADIL for comparison